Big bonus bonanza coming up at Actavis

The company's management team could see $101 million in bonuses.

By Nicole Gray • April 2, 2015

Partners wanted: Roche seeking collaborators in cancer immunotherapy

Severin Schwan, CEO of the Swiss drugmaker, is looking for collaborative research relationships to develop a range of immunooncology-based cancer drugs.

By Nicole Gray • April 2, 2015

Merck Serono and Intrexon initiate $941 million CAR-T deal

The CAR-T boom rages on.

By Nicole Gray • March 31, 2015

What UnitedHealth's $12.8B Catamaran deal means for pharma's pricing war

The marketing landscape is just going to get harder for the industry.

By Nicole Gray • March 31, 2015

The M&A train rolls on: Teva to buy American CNS drug maker for $3.2B

U.S.-based Auspex Pharma makes drugs for CNS disorders such as Huntington's and Tourette's.

By Sy Mukherjee • March 30, 2015

Celgene emerges as biotech partnering king of 2014

Under the leadership of George Golumbeski, the biotech forged 10 licensing deals last year.

By Nicole Gray • March 18, 2015

Allergan CEO Pyott heading for the exits as Actavis finalizes buyout

The times are changing over at Allergan.

By Nicole Gray • March 18, 2015

UPDATE: Valeant successfully fends off Endo, seals deal with Salix

Salix is walking away with even more cash from Valeant than it expected, spurred by a last-minute poaching bid from Endo.

By Sy Mukherjee • March 16, 2015

Bill & Melinda Gates Foundation bets big on CureVac's mRNA platform

The foundation is investing $52 million in the Germany-based company.

By Nicole Gray • March 13, 2015

Zogenix selling painkiller Zohydro to Pernix in huge deal

Pernix Therapeutics could end up paying a total of $383.5 million for the opioid painkiller Zohydro.

By Nicole Gray • March 12, 2015

Concordia acquiring Covis assets for $1.2 billion

The Canada-based company is buying 18 branded and authorized generic products from the privately held Covis Pharmaceuticals. 

By Nicole Gray • March 11, 2015

Why CNS drug maker Acadia's shares soared on Tuesday

Rumors of a buy-out have been propelled by Acadia canceling two investor's conferences in a row, sending its stock soaring.

By Nicole Gray • March 11, 2015

Ackman becomes Valeant's 5th largest shareholder with $3.3B gamble

With Ackman's latest investment, Pershing Square now owns 4.9% of Valeant.

By Nicole Gray • March 9, 2015

AbbVie beats out J&J, will buy Pharmacyclics for $21B to boost cancer pipeline

With lower Humira sales on the horizon, AbbVie will get a big boost from Pharmacyclics' expected cancer blockbuster Imbruvica.

By Sy Mukherjee • March 5, 2015

The post-acquisition cuts begin: Valeant lays off 77 Dendreon employees

As of February 23, Valeant started laying off the 77 Dendreon employees slated for termination after the now-defunct company's $495 million acquisition by Valeant.

By Nicole Gray • March 4, 2015

AZ board to CEO Soriot: Want that big bonus? Show us the money

After successfully staving off a Pfizer takeover last year, the AZ CEO promised revenues of $45 billion by 2023. But sales are down, and now Soriot's bonus is at stake.

By Nicole Gray • March 3, 2015

Gilead seals generic Sovaldi deal with Natco, NICE rec for Harvoni in UK

India-based Natco Pharma will sell generic Sovaldi (sofosbuvir) and other hep C drugs in 91 countries. And Harvoni will come at a steep discount compared to the U.S. in the UK.

By Nicole Gray • March 3, 2015

Ousted Sanofi chief Chris Viebacher lands at PureTech

Viehbacher is joining the company, a Boston-based healthcare R&D firm, as a member of its Board of Directors.

By Nicole Gray • March 2, 2015

Pharmacyclics surges on news of potential sale to J&J, Novartis

It could become the biggest biotech deal since Sanofi/Genzyme.

By Nicole Gray • Feb. 26, 2015

Merck, MPP team up to provide low-cost HIV pediatric meds in poor countries

Merck's Isentress (raltegravir) is the only integrase inhibitor approved for pediatric treatment.

By Nicole Gray • Feb. 25, 2015

French government slams Sanofi over new CEO's pay

One government spokesperson called Olivier Brandicourt's pay package, which includes a $4.5 million entry bonus, "incomprehensible."

By Nicole Gray • Feb. 25, 2015

Shire keeps acquisition train rolling with $70M Meritage Pharma deal

Through the Meritage acquisition, Shire is gaining a phase 3 treatment for a rare GI disorder.

By Nicole Gray • Feb. 25, 2015

Platinum parachute? Allergan CEO Pyott could get $100M exit fee

Actavis has said that it will replace most of Allergan's executives with its own post-merger.  

By Nicole Gray • Feb. 25, 2015

Pfizer planning more layoffs in R&D

The company also says it will be adding positions in immuno-oncology and gene therapy as part of a new round of restructuring.  

By Sy Mukherjee • Feb. 24, 2015

Duchenne, orphan drug maker PTC Therapeutics fielding takeover bids

According to an exclusive report from Reuters.

By Nicole Gray • Feb. 24, 2015